Phase 2 Rare Disease Trial, Recruiting NCT01356290 Sponsor: Medical University of Vienna Condition: Rare Disease
Back to Rare Disease

Phase 2 Rare Disease Trial, Recruiting

NCT01356290
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have a brain tumor (medulloblastoma, ependymoma, ATRT, or another central nervous system tumor) that has come back or continued to grow after previous treatment.
  • Your tumor type was confirmed by a biopsy or tissue sample, either when first diagnosed or when the tumor came back.
  • For one group (Stratum IV), the medulloblastoma must also be confirmed by a specific molecular test called methylation analysis (confirm with trial site).
  • You are female or male, and were under 20 years old at the time of your original diagnosis.
  • Your liver, kidneys, and blood cell counts are within acceptable ranges as tested by blood tests (confirm with trial site for specific values).
  • You are well enough to carry out at least some daily activities, as measured by a standard health scoring scale (a score of 50 or above out of 100, or an equivalent child-friendly scale for those under 12).
  • You (and/or your parent or legal guardian) have given written agreement to take part in the trial.

Who may not be able to join:

  • You rely on a VP shunt or subdural peritoneal shunt to drain fluid from your brain (though you may still be considered for a different group in the trial — confirm with trial site).
  • You have previously been treated with the drugs temozolomide or irinotecan (though you may still be considered for a different group — confirm with trial site).
  • You currently have an active infection.
  • You are pregnant or breastfeeding.
  • You have already started receiving treatment specifically for your current relapse (note: surgery before starting this trial may still be allowed — confirm with trial site).
  • You have a known allergy to any of the medicines used in this trial.
  • You currently have an active stomach ulcer.
  • You have a significant heart or blood pressure problem that is not controlled by standard treatment.
  • You are expected to need major planned surgery during the course of the trial.
  • You have any other medical condition that would make it unsafe to receive the trial treatment (confirm with trial site).
  • You have a surgical wound that has not healed properly.
  • You have a broken bone that has not healed properly.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Andreas Peyrl, MD, Medical University of Vienna

Phone: +43 1 40400

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 April 2014
Est. completion
1 April 2030

Where this trial is recruiting

🇦🇹 Austria 🇨🇿 Czechia 🇩🇰 Denmark 🇫🇷 France 🇳🇴 Norway 🇪🇸 Spain 🇸🇪 Sweden 🇺🇸 United States

Primary endpoints

Efficacy

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov